Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

BRENDA Home
show all | hide all No of entries

Information on EC 2.4.2.8 - hypoxanthine phosphoribosyltransferase and Organism(s) Plasmodium falciparum and UniProt Accession P20035

for references in articles please use BRENDA:EC2.4.2.8
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
     2 Transferases
         2.4 Glycosyltransferases
             2.4.2 Pentosyltransferases
                2.4.2.8 hypoxanthine phosphoribosyltransferase
IUBMB Comments
Guanine and purine-6-thiol can replace hypoxanthine.
Specify your search results
Select one or more organisms in this record: ?
This record set is specific for:
Plasmodium falciparum
UNIPROT: P20035
Show additional data
Do not include text mining results
Include (text mining) results
Include results (AMENDA + additional results, but less precise)
Word Map
The taxonomic range for the selected organisms is: Plasmodium falciparum
The enzyme appears in selected viruses and cellular organisms
Synonyms
hprt, hgprt, hypoxanthine-guanine phosphoribosyltransferase, hprt1, hypoxanthine phosphoribosyltransferase, hypoxanthine-guanine phosphoribosyl transferase, hypoxanthine phosphoribosyl transferase, hypoxanthine guanine phosphoribosyltransferase, hgprtase, guanine phosphoribosyltransferase, more
SYNONYM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
hypoxanthine guanine phosphoribosyltransferase
-
hypoxanthine guanine xanthine phosphoribosyltransferase
-
hypoxanthine-guanine phosphoribosyltransferase
-
hypoxanthine-guanine-xanthine phosphoribosyltransferase
-
6-hydroxypurine phosphoribosyltransferase
-
-
-
-
6-mercaptopurine phosphoribosyltransferase
-
-
-
-
GMP pyrophosphorylase
-
-
-
-
guanine phosphoribosyltransferase
-
-
-
-
guanine-hypoxanthine phosphoribosyltransferase
-
-
-
-
guanosine 5'-phosphate pyrophosphorylase
-
-
-
-
guanosine phosphoribosyltransferase
-
-
-
-
guanylate pyrophosphorylase
-
-
-
-
guanylic pyrophosphorylase
-
-
-
-
HGPRT
HGPRTase
-
-
-
-
HGXPRT
hypoxanthine guanine phosphoribosyltransferase
-
-
hypoxanthine guanine xanthine phosphoribosyltransferase
hypoxanthine-guanine phosphoribosyltransferase
hypoxanthine-guanine-(xanthine) phosphoribosyltransferase
-
hypoxanthine-guanine-xanthine phosphoribosyltransferase
hypoxanthine-guanine-[xanthine]-phosphoribosyltransferase
-
IMP pyrophosphorylase
-
-
-
-
IMP-GMP pyrophosphorylase
-
-
-
-
inosinate pyrophosphorylase
-
-
-
-
inosine 5'-phosphate pyrophosphorylase
-
-
-
-
inosinic acid pyrophosphorylase
-
-
-
-
inosinic pyrophosphorylase
-
-
-
-
PF3D7_1012400
phosphoribosyltransferase, 6-mercaptopurine
-
-
-
-
phosphoribosyltransferase, hypoxanthine
-
-
-
-
purine-6-thiol phosphoribosyltransferase
-
-
-
-
transphosphoribosidase
-
-
-
-
additional information
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
IMP + diphosphate = hypoxanthine + 5-phospho-alpha-D-ribose 1-diphosphate
show the reaction diagram
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
pentosyl group transfer
-
-
-
-
SYSTEMATIC NAME
IUBMB Comments
IMP:diphosphate phospho-D-ribosyltransferase
Guanine and purine-6-thiol can replace hypoxanthine.
CAS REGISTRY NUMBER
COMMENTARY hide
9016-12-0
-
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
GMP + diphosphate
guanine + 5-phospho-alpha-D-ribose 1-diphosphate
show the reaction diagram
-
-
-
r
guanine + 5-phospho-alpha-D-ribose 1-diphosphate
GMP + diphosphate
show the reaction diagram
hypoxanthine + 5-phospho-alpha-D-ribose 1-diphosphate
IMP + diphosphate
show the reaction diagram
IMP + diphosphate
hypoxanthine + 5-phospho-alpha-D-ribose 1-diphosphate
show the reaction diagram
-
-
-
r
xanthine + 5-phospho-alpha-D-ribose 1-diphosphate
? + diphosphate
show the reaction diagram
xanthine + 5-phospho-alpha-D-ribose 1-diphosphate
XMP + diphosphate
show the reaction diagram
XMP + diphosphate
xanthine + 5-phospho-alpha-D-ribose 1-diphosphate
show the reaction diagram
-
-
-
r
allopurinol + 5-phospho-alpha-D-ribose 1-diphosphate
allopurinol ribonucleoside 5'-monophosphate + diphosphate
show the reaction diagram
-
-
-
?
guanine + 5-phospho-alpha-D-ribose 1-diphosphate
GMP + diphosphate
show the reaction diagram
guanosine + 5-phospho-alpha-D-ribose 1-diphosphate
GMP + diphosphate
show the reaction diagram
hypoxanthine + 5-phospho-alpha-D-ribose 1-diphosphate
IMP + diphosphate
show the reaction diagram
xanthine + 5-phospho-alpha-D-ribose 1-diphosphate
? + diphosphate
show the reaction diagram
-
-
-
-
?
xanthine + 5-phospho-alpha-D-ribose 1-diphosphate
xanthosine 5'-phosphate + diphosphate
show the reaction diagram
xanthine + 5-phospho-alpha-D-ribose 1-diphosphate
XMP + diphosphate
show the reaction diagram
additional information
?
-
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
GMP + diphosphate
guanine + 5-phospho-alpha-D-ribose 1-diphosphate
show the reaction diagram
-
-
-
r
guanine + 5-phospho-alpha-D-ribose 1-diphosphate
GMP + diphosphate
show the reaction diagram
hypoxanthine + 5-phospho-alpha-D-ribose 1-diphosphate
IMP + diphosphate
show the reaction diagram
IMP + diphosphate
hypoxanthine + 5-phospho-alpha-D-ribose 1-diphosphate
show the reaction diagram
-
-
-
r
xanthine + 5-phospho-alpha-D-ribose 1-diphosphate
? + diphosphate
show the reaction diagram
-
-
-
?
xanthine + 5-phospho-alpha-D-ribose 1-diphosphate
XMP + diphosphate
show the reaction diagram
XMP + diphosphate
xanthine + 5-phospho-alpha-D-ribose 1-diphosphate
show the reaction diagram
-
-
-
r
guanine + 5-phospho-alpha-D-ribose 1-diphosphate
GMP + diphosphate
show the reaction diagram
guanosine + 5-phospho-alpha-D-ribose 1-diphosphate
GMP + diphosphate
show the reaction diagram
hypoxanthine + 5-phospho-alpha-D-ribose 1-diphosphate
IMP + diphosphate
show the reaction diagram
xanthine + 5-phospho-alpha-D-ribose 1-diphosphate
? + diphosphate
show the reaction diagram
-
-
-
-
?
xanthine + 5-phospho-alpha-D-ribose 1-diphosphate
xanthosine 5'-phosphate + diphosphate
show the reaction diagram
xanthine + 5-phospho-alpha-D-ribose 1-diphosphate
XMP + diphosphate
show the reaction diagram
additional information
?
-
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
additional information
-
no activation by Ca2+
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(3-hydroxy-2-[[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]methyl]propyl)phosphonic acid
-
3-((7-hydroxy-1H-pyrazolo[4,3-d]pyrimidin-3-yl)methylamino)propylphosphonate
-
9-deazaguanine
uncompetitive inhibitor
GMP
competitive inhibitor with respect to guanine, xanthine, and 5-phospho-alpha-D-ribose 1-diphosphate
[(+/-)-2(R/S)-3-hydroxy-2-[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]propoxy]phosphonic acid
-
[(+/-)-2(R/S)-[([2-chloro-4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]-3-hydroxypropoxy]phosphonic acid
-
[(2R)-2-[([2-amino-4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]-3-hydroxypropoxy]phosphonic acid
-
[(2R)-3-hydroxy-2-[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]propoxy]phosphonic acid
-
[(2S)-2-[([2-amino-4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]-3-hydroxypropoxy]phosphonic acid
-
[(2S,3R)-2,4-dihydroxy-3-[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]butoxy]phosphonic acid
-
[(3R)-4-hydroxy-3-[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]butyl]phosphonic acid
-
[(3S)-1,1-difluoro-4-hydroxy-3-[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]butyl]phosphonic acid
-
[(3S)-3-[([2-amino-4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]-1,1-difluoro-4-hydroxybutyl]phosphonic acid
-
[(3S)-4-hydroxy-3-[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]butyl]phosphonic acid
-
[2-hydroxy-3-[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]propyl] phosphonic acid
-
[2-[(2-[4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]ethyl)amino]ethyl]phosphonic acid
-
[2-[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]ethoxy]phosphonic acid
-
[3-hydroxy-2-[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]-2-(hydroxymethyl)propoxy]phosphonic acid
-
[3-[(2-[4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]ethyl)amino]propyl]phosphonic acid
-
[[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]butyl]phosphonic acid
-
[[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]ethyl]phosphonic acid
-
[[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]methyl]phosphonic acid
-
[[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]pentyl]phosphonic acid
-
[[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]propyl]phosphonic acid
-
(1S)-1-(9-deazaguanin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol 5-phosphate
-
-
(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol 5-phosphate
-
-
(2-[(3R,4R)-3-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)-4-[(2R)-2-hydroxy-2-phosphonoethoxy]pyrrolidin-1-yl]-2-oxoethyl)phosphonic acid
enzyme-bound crystal structure analysis
(2-[3-(8-bromoguanin-9-yl)-2-(2-(bishydroxyphosphoryl)-ethoxy)propoxy]ethyl)phosphonic acid
-
(2-[[(3R,4R)-4-(6-oxo-1,6-dihydro-9H-purin-9-yl)-1-(phosphonoacetyl)pyrrolidin-3-yl]oxy]ethyl)phosphonic acid
-
(3-[[(4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]amino]propyl)phosphonic acid
-
competitive. 466fold lower affinity for human enzyme. Treatment of cultured parasites with the bis-pavalate of the inhibitor as a prodrug inhibits growth with an IC50 of 45 microM
(R)-9-[2-(phosphonomethoxy)propyl]hypoxanthine
-
-
(R)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]-8-bromoguanine
-
-
(R)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]guanine
-
is toxic to cells and arrests cell growth
(S)-3-(guanin-9-yl)-pyrrolidin-N-ylacetylphosphonic acid
-
(S)-9-[2-(phosphonomethoxy)propyl]guanine
-
-
(S)-9-[2-(phosphonomethoxy)propyl]hypoxanthine
-
-
(S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]-8-azaguanine
-
-
(S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]-8-bromoguanine
-
-
(S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]guanine
([2-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-3-(2-phosphonoethoxy)propoxy]methyl)phosphonic acid
-
([2-[(6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-3-(2-phosphonoethoxy)propoxy]methyl)phosphonic acid
-
([3-(7-deazaguanine-9-yl)-2-((2-phosphonoethoxy)methyl)propoxy]methyl)phosphonic acid
sodium salt
([3-(7-deazahypoxanthine-9-yl)-2-((2-phosphonoethoxy)methyl)propoxy]methyl)phosphonic acid
sodium salt
([3-(8-bromoguanine-9-yl)-2-((2-phosphonoethoxy)methyl)propoxy]methyl)phosphonic acid
sodium salt
([3-(8-bromohypoxanthine-9-yl)-2-((2-phosphonoethoxy)methyl)propoxy]methyl)phosphonic acid
sodium salt
([3-(guanine-9-yl)-2-((2-phosphonoethoxy)-methyl)propoxy]methyl)phosphonic acid
sodium salt
([3-(hypoxanthine-9-yl)-2-((2-phosphonoethoxy)methyl)propoxy]methyl)phosphonic acid
sodium salt
6-methylheptyl hydrogen {[2-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)ethoxy]methyl}phosphonate
-
-
9-[2-(2-phosphonoethoxy)ethyl]guanine
-
-
9-[2-(2-phosphonoethoxy)ethyl]hypoxanthine
-
-
9-[2-(phosphonomethoxy)-3-fluoro-propyl]guanine
-
-
9-[2-(phosphonomethoxy)ethyl]-6-thioguanine
-
-
9-[2-(phosphonomethoxy)ethyl]-7-deaza-8-azahypoxanthine
-
-
9-[2-(phosphonomethoxy)ethyl]-8-azaguanine
-
-
9-[2-(phosphonomethoxy)ethyl]-8-bromoguanine
-
-
9-[2-(phosphonomethoxy)ethyl]guanine
9-[2-(phosphonomethoxy)ethy]-8-hydroxyguanine
-
-
acyclic nucleoside phosphonates
-
analogues of the nucleotide reaction product, comprising a purine base joined by a linker to a phosphonate moiety, inhibitor design and potencies, overview. Selectivity for the parasite enzyme of up to 58 compared to the Homo sapiens enzyme, overview, design of potent and selective acyclic nucleoside phosphonates inhibitors of Plasmodium falciparum HGXPRT as antimalarial drug leads
cyclic (R)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]guanine
-
is toxic to cells and arrests cell growth
cyclic (S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]guanine
-
is toxic to cells and arrests cell growth
diethyl (2S,15S)-2,15-dibenzyl-4,13-bis[[(2S)-1-ethoxy-1-oxo-3-phenylpropan-2-yl]amino]-4,13-dioxo-8-[(4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl]-6,10-dioxa-3,14-diaza-4lambda5,13lambda5-diphosphahexadecane-1,16-dioate
prodrug
diethyl (2S,15S)-2,15-dibenzyl-4,13-bis[[(2S)-1-ethoxy-1-oxo-3-phenylpropan-2-yl]amino]-4,13-dioxo-8-[(6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-6,10-dioxa-3,14-diaza-4lambda5,13lambda5-diphosphahexadecane-1,16-dioate
prodrug
diethyl (2S,15S)-2,15-dibenzyl-8-[(8-bromo-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-4,13-bis[[(2S)-1-ethoxy-1-oxo-3-phenylpropan-2-yl]amino]-4,13-dioxo-6,10-dioxa-3,14-diaza-4lambda5,13lambda5-diphosphahexadecane-1,16-dioate
prodrug
diethyl (2S,15S)-4,13-bis[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-4,13-dioxo-8-[(6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-2,15-bis(2-phenylethyl)-6,10-dioxa-3,14-diaza-4lambda5,13lambda5-diphosphahexadecane-1,16-dioate
-
diethyl (2S,15S)-8-[(2-amino-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl]-2,15-dibenzyl-4,13-bis[[(2S)-1-ethoxy-1-oxo-3-phenylpropan-2-yl]amino]-4,13-dioxo-6,10-dioxa-3,14-diaza-4lambda5,13lambda5-diphosphahexadecane-1,16-dioate
prodrug
diethyl (2S,15S)-8-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-2,15-dibenzyl-4,13-bis[[(2S)-1-ethoxy-1-oxo-3-phenylpropan-2-yl]amino]-4,13-dioxo-6,10-dioxa-3,14-diaza-4lambda5,13lambda5-diphosphahexadecane-1,16-dioate
prodrug
diethyl (2S,15S)-8-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-2,15-dibenzyl-4,13-bis[[(2S)-1-ethoxy-1-oxo-3-phenylpropan-2-yl]amino]-4,13-dioxo-7,10-dioxa-3,14-diaza-4lambda5,13lambda5-diphosphahexadecane-1,16-dioate
prodrug
diethyl (2S,15S)-8-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-4,13-bis[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-4,13-dioxo-2,15-bis(2-phenylethyl)-6,10-dioxa-3,14-diaza-4lambda5,13lambda5-diphosphahexadecane-1,16-dioate
-
diethyl (2S,15S)-8-[(2-amino-8-bromo-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-2,15-dibenzyl-4,13-bis[[(2S)-1-ethoxy-1-oxo-3-phenylpropan-2-yl]amino]-4,13-dioxo-7,10-dioxa-3,14-diaza-4lambda5,13lambda5-diphosphahexadecane-1,16-dioate
prodrug
guanine ribose 5'-phosphate
-
-
Hg2+
-
complete inhibition at 3 mM after 3 min at 0°C
hypoxanthine ribose 5'-phosphate
-
-
iso-mukaadial acetate
-
KCl
-
inactivation
propan-2-yl hydrogen {[2-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)ethoxy]methyl}phosphonate
-
-
triethyl-2-phosphonobutyrate
-
ursolic acid acetate
-
[(1S)-1-hydroxy-2-[[(3R,4R)-4-(6-oxo-1,6-dihydro-9H-purin-9-yl)-1-(phosphonoacetyl)pyrrolidin-3-yl]oxy]ethyl]phosphonic acid
-
[(3S)-4-hydroxy-3-[[(4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]amino]butyl]phosphonic acid
-
competitive. 592fold lower affinity for human enzyme
[3-(guanine-9-yl)-2-((2-phosphonoethoxy)methyl)propoxy]methylphosphonic acid
-
[3R,4R]-4-guanin-9-yl-3-((S)-2-hydroxy-2-phosphonoethyl)oxy-1-N-(phosphonopropionyl)pyrrolidine
-
[[2-[(6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]propane-1,3-diyl]bis(oxymethylene)]bis(phosphonic acid)
-
additional information
-
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
IMP
activates the enzyme, activating effects on wild-type and mutant enzymes, overview. Upon activation of the mutants with IMP, the lag phase disappears, while an increase in the specific activity values appears. Although activation of wild-type and mutants by IMP increases their catalytic efficiency by about 100fold, it is found that the kcat/Km values for the mutants drop by 5.7 to 75fold when compared with the wild-type enzyme
additional information
-
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.053 - 1.548
5-phospho-alpha-D-ribose 1-diphosphate
0.0039 - 0.0042
diphosphate
0.0011 - 0.0048
guanine
0.0018 - 0.0075
hypoxanthine
0.0016 - 0.007
IMP
0.036 - 0.332
xanthine
0.025 - 3.668
5-phospho-alpha-D-ribose 1-diphosphate
0.0117
allopurinol
-
recombinant enzyme
0.001 - 0.362
guanine
0.0009 - 0.06
hypoxanthine
0.17 - 0.853
xanthine
additional information
additional information
-
-
-
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.04 - 1.6
5-phospho-alpha-D-ribose 1-diphosphate
0.06 - 25.5
guanine
0.1 - 7.1
hypoxanthine
0.0036 - 0.0042
IMP
0.08 - 1.6
xanthine
0.1 - 1.6
5-phospho-alpha-D-ribose 1-diphosphate
0.013 - 1.2
guanine
0.073 - 1.13
hypoxanthine
0.062 - 2.9
xanthine
kcat/KM VALUE [1/mMs-1]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.18 - 30
5-phospho-alpha-D-ribose 1-diphosphate
0.9 - 1
diphosphate
0.6 - 2.2
IMP
2.6 - 16
xanthine
0.036 - 64
5-phospho-alpha-D-ribose 1-diphosphate
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.00049
(3-hydroxy-2-[[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]methyl]propyl)phosphonic acid
at pH 7.6 and 37°C
0.0000276
3-((7-hydroxy-1H-pyrazolo[4,3-d]pyrimidin-3-yl)methylamino)propylphosphonate
at pH 7.6 and 37°C
0.000019
[(+/-)-2(R/S)-3-hydroxy-2-[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]propoxy]phosphonic acid
at pH 7.6 and 37°C
0.0094
[(+/-)-2(R/S)-[([2-chloro-4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]-3-hydroxypropoxy]phosphonic acid
at pH 7.6 and 37°C
0.0000143
[(2R)-2-[([2-amino-4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]-3-hydroxypropoxy]phosphonic acid
at pH 7.6 and 37°C
0.0000024
[(2R)-3-hydroxy-2-[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]propoxy]phosphonic acid
at pH 7.6 and 37°C
0.00065
[(2S)-2-[([2-amino-4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]-3-hydroxypropoxy]phosphonic acid
at pH 7.6 and 37°C
0.00098
[(2S,3R)-2,4-dihydroxy-3-[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]butoxy]phosphonic acid
at pH 7.6 and 37°C
0.0000012 - 0.0000234
[(3R)-4-hydroxy-3-[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]butyl]phosphonic acid
0.000087
[(3S)-1,1-difluoro-4-hydroxy-3-[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]butyl]phosphonic acid
at pH 7.6 and 37°C
0.0001
[(3S)-3-[([2-amino-4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]-1,1-difluoro-4-hydroxybutyl]phosphonic acid
at pH 7.6 and 37°C
0.00000065
[(3S)-4-hydroxy-3-[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]butyl]phosphonic acid
at pH 7.6 and 37°C
0.0000091
[2-hydroxy-3-[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]propyl] phosphonic acid
at pH 7.6 and 37°C
0.00062
[2-[(2-[4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]ethyl)amino]ethyl]phosphonic acid
at pH 7.6 and 37°C
0.0144
[2-[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]ethoxy]phosphonic acid
at pH 7.6 and 37°C
0.0153
[3-hydroxy-2-[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]-2-(hydroxymethyl)propoxy]phosphonic acid
at pH 7.6 and 37°C
0.02
[3-[(2-[4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]ethyl)amino]propyl]phosphonic acid
at pH 7.6 and 37°C
0.00049
[[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]butyl]phosphonic acid
at pH 7.6 and 37°C
0.0019
[[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]ethyl]phosphonic acid
at pH 7.6 and 37°C
0.02
[[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]methyl]phosphonic acid
at pH 7.6 and 37°C
0.0086
[[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]pentyl]phosphonic acid
at pH 7.6 and 37°C
0.0000106
[[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]propyl]phosphonic acid
at pH 7.6 and 37°C
0.00001 - 0.00006
(2-[(3R,4R)-3-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)-4-[(2R)-2-hydroxy-2-phosphonoethoxy]pyrrolidin-1-yl]-2-oxoethyl)phosphonic acid
0.000014 - 0.00008
(2-[[(3R,4R)-4-(6-oxo-1,6-dihydro-9H-purin-9-yl)-1-(phosphonoacetyl)pyrrolidin-3-yl]oxy]ethyl)phosphonic acid
0.00001
(3-[[(4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]amino]propyl)phosphonic acid
-
pH 7.6, 37°C
0.02
(R)-9-[2-(phosphonomethoxy)propyl]-8-bromoguanine
-
pH 7.4, 25°C
0.4373
(R)-9-[2-(phosphonomethoxy)propyl]hypoxanthine
-
pH 8.5, 25°C
0.0006
(R,S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]guanine
-
pH 7.4, 25°C
0.0004 - 0.0026
(S)-3-(guanin-9-yl)-pyrrolidin-N-ylacetylphosphonic acid
0.045
(S)-9-[2-(phosphonomethoxy)propyl]-8-azaguanine
-
above, pH 7.4, 25°C
0.011
(S)-9-[2-(phosphonomethoxy)propyl]-8-bromoguanine
-
pH 7.4, 25°C
0.0648
(S)-9-[2-(phosphonomethoxy)propyl]hypoxanthine
-
pH 8.5, 25°C
0.0284
(S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]guanine
-
pH 8.5, 25°C
0.5
6-methylheptyl hydrogen {[2-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)ethoxy]methyl}phosphonate
-
above, pH 7.4, 25°C
0.0001
9-[2-(2-phosphonoethoxy)ethyl]guanine
-
pH 7.4, 25°C
0.0003
9-[2-(2-phosphonoethoxy)ethyl]hypoxanthine
-
pH 7.4, 25°C
0.0036
9-[2-(phosphonomethoxy)-3-fluoro-propyl]guanine
-
pH 8.5, 25°C
0.1
9-[2-(phosphonomethoxy)ethyl]-6-thioguanine
-
above, pH 7.4, 25°C
0.0072
9-[2-(phosphonomethoxy)ethyl]-7-deaza-8-azahypoxanthine
-
pH 7.4, 25°C
0.003
9-[2-(phosphonomethoxy)ethyl]-8-azaguanine
-
pH 7.4, 25°C
0.01
9-[2-(phosphonomethoxy)ethyl]-8-bromoguanine
-
pH 7.4, 25°C
0.0016 - 0.0189
9-[2-(phosphonomethoxy)ethyl]guanine
0.0012
9-[2-(phosphonomethoxy)ethy]-8-hydroxyguanine
-
pH 7.4, 25°C
0.001 - 0.0014
cyclic (R)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]guanine
0.008 - 0.0377
cyclic (S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]guanine
0.01
guanine ribose 5'-phosphate
-
pH 7.4, 25°C
0.0036
hypoxanthine ribose 5'-phosphate
-
pH 7.4, 25°C
0.2
propan-2-yl hydrogen {[2-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)ethoxy]methyl}phosphonate
-
above, pH 7.4, 25°C
0.000002 - 0.000006
[(1S)-1-hydroxy-2-[[(3R,4R)-4-(6-oxo-1,6-dihydro-9H-purin-9-yl)-1-(phosphonoacetyl)pyrrolidin-3-yl]oxy]ethyl]phosphonic acid
0.00000065
[(3S)-4-hydroxy-3-[[(4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]amino]butyl]phosphonic acid
-
pH 7.6, 37°C
0.000006
[3-(guanine-9-yl)-2-((2-phosphonoethoxy)methyl)propoxy]methylphosphonic acid
pH 7.4, temperature not specified in the publication
0.000007 - 0.000008
[3R,4R]-4-guanin-9-yl-3-((S)-2-hydroxy-2-phosphonoethyl)oxy-1-N-(phosphonopropionyl)pyrrolidine
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
0.0000021 - 0.0000072
-
purified native enzyme
0.032
-
purified recombinant chimeric enzyme DS1, substrate guanine
0.147
-
purified recombinant chimeric enzyme DS1, substrate xanthine
0.226
-
purified recombinant chimeric enzyme DS1, substrate hypoxanthine
1.4
-
purified recombinant enzyme, substrate hypoxanthine, pH 8.0
1.45
-
purified recombinant enzyme, substrate hypoxanthine, in presence of 0.008 mM IMP, after 6 h
3
-
purified recombinant enzyme, substrates allopurinol and xanthine, pH 8.0
5.22
-
purified recombinant enzyme, substrate hypoxanthine, in presence of 0.038 mM IMP, after 48 h
5.4
-
purified recombinant enzyme, substrate guanine, pH 8.0
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
22
-
assay at room temperature
additional information
-
-
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
physiological function
additional information
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
26000
4 * 26000, calculated from amino acid sequence
SUBUNIT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
homotetramer
4 * 26000, calculated from amino acid sequence
monomer or dimer
the recombinant chimeric enzyme exists as a mixture of monomeric and dimeric protein in solution, but shifts to a tetramer on addition of phosphoribosyl diphosphate
tetramer
the recombinant chimeric enzyme exists as a mixture of monomeric and dimeric protein in solution, but shifts to a tetramer on addition of phosphoribosyl diphosphate
dimer
-
2 * 26229-26232, in presence of KCl, SDS-PAGE, mass spectroscopy and DNA sequence determination
tetramer
additional information
CRYSTALLIZATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
recombinant chimeric mutant enzyme complex with the product GMP, 12 mg/ml protein and 5 mM GMP in 0.1 M Tris, pH 8.0, and 2.0 M ammonium sulfate, 2-5 days, X-ray diffraction structure determination and analysis at 2.8 A resolution, modeling
purified recombinant enzyme PvHGPRT in complex with inhibitor [3R,4R]-4-guanin-9-yl-3-((S)-2-hydroxy-2-phosphonoethyl)oxy-1-N-(phosphonopropionyl)pyrrolidine, 21 mg/ml protein is incubated with 6.4 mM inhibitor on ice for 5 min, hanging drop method, mixing of 0.001 ml of protein and inhibitor with 0.001 ml of reservoir solution containing 0.3 M potassium thiocyanate, 0.1 M Bis-tris propane, pH 8.5, 18°C, X-ray diffraction structure determination and analysis at 2.85 A resolution, molecular replacement using the protein coordinates of subunit A of human HGPRT in complex with [(2-[(guanin-9H-yl)methyl]-propane-1,3-diyl)bis(oxy)]bis-(methylene)diphosphonic acid as template (PDB ID 4IJQ), model building
ultraviolet resonance Raman spectroscopy study on the complexes of enzyme with products IMP, GMP, and XMP, both in Homo sapiens and Plasmodium falciparum, in resonance with the purine nucleobase electronic absorption. Human hypoxanthine guanine phosphoribosyltransferase catalyzes the phosphoribosylation of guanine and hypoxanthine, while the Plasmodium falciparum enzyme acts on xanthine as well. Spectra of bound nucleotides show that the enzyme distorts the structure of the nucleotides. The distorted structure resembles that of the deprotonated nucleotide. The two proteins assemble similar active sites for their common substrates. While the human enzyme does not bind XMP, Plasmodium falciparum hypoxanthine guanine phosphoribosyltransferase perturbs the pKa of bound XMP
-
PROTEIN VARIANTS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
F197W
the mutant shows reduced activity compared tot he wild type enzyme
W181S/F197W
the mutant shows reduced activity compared tot he wild type enzyme
W181F
site-directed mutagenesis of residue Trp181 in loop III', the mutant shows an over 5fold decreased xanthine phosphoribosylation activity compared to wild-type and an increase in Km for 5-phospho-alpha-D-ribose 1-diphosphate (PRPP)
W181S
site-directed mutagenesis of residue Trp181 in loop III', the mutant shows an over 5fold decreased xanthine phosphoribosylation activity compared to wild-type and an increase in Km for 5-phospho-alpha-D-ribose 1-diphosphate (PRPP)
W181T
site-directed mutagenesis of residue Trp181 in loop III', the mutant shows an over 10fold decreased xanthine phosphoribosylation activity compared to wild-type and an increase in Km for 5-phospho-alpha-D-ribose 1-diphosphate (PRPP)
W181Y
site-directed mutagenesis of residue Trp181 in loop III', the mutant shows an over 5fold decreased xanthine phosphoribosylation activity compared to wild-type and an increase in Km for 5-phospho-alpha-D-ribose 1-diphosphate (PRPP)
additional information
TEMPERATURE STABILITY
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
additional information
-
-
GENERAL STABILITY
ORGANISM
UNIPROT
LITERATURE
activation by substrate and product IMP destabilizes the enzyme, the unactivated ligand-free enzyme is more stable
-
DTT and hypoxanthine stabilize
-
STORAGE STABILITY
ORGANISM
UNIPROT
LITERATURE
4°C, freshly purified enzyme, 10 mM phosphate, pH 6.8, 10 mM DTT, 1 mM 5-phosphoribosyl 1-diphosphate, rapid loss of 90% activity within 48 h
-
5°C, purified enzyme, 10 mM phosphate, pH 6.8, 1 mM DTT, 0.2 mM 5-phosphoribosyl 1-diphosphate, 0.06 hypoxanthine, loss of 7% activity after 4-8 weeks
-
PURIFICATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
recombinant chimeric mutant enzyme from Escherichia coli strain Su609 by anion exchange chromatography
native enzyme by anion exchange and cation exchange chromatographies and affinity chromatography on immobilized Reactive Red 120, method development, overview, recombinant His-tagged enzyme from Escherichia coli strain BL21(DE3) by nickel affinity chromatography
-
recombinant from Escherichia coli , large scale
-
recombinant His6-tagged enzyme from Escherichia coli strain BL21(DE3) by nickel affinity xhromatography
recombinant wild-type and mutant L44F from Escherichia coli
-
recombinant wild-type and mutant L44F from Escherichia coli, the enzyme shows very low activity
-
CLONED (Commentary)
ORGANISM
UNIPROT
LITERATURE
expressed in Escherichia coli strain Sphi609 cells
overexpression of the chimeric mutant enzyme in Escherichia coli strain Su609
expression as His-tagged enzyme in Escherichia coli strain BL21(DE3)
-
expression in Escherichia coli
-
expression of wild-type and chimeric enzymes in enzyme-deficient Escherichia coli strain, complementation study, overexpression of chimeric mutant DS1
-
expression of wild-type and mutant enzyme in Escherichia coli, complementation of an enzyme-deficient Escherichia coli strain by the wild-type and mutant L44F at growth temperatures 20°C and 37°C, and at 42°C only by the wild-type enzyme
-
expression of wild-type and mutant enzyme in Escherichia coli, functional complementation study
-
gene PF3D7_1012400, recombinant expression of His6-tagged enzyme in Escherichia coli strain BL21(DE3)
gene PF3D7_1012400, recombinant expression of N-terminally His6-tagged enzyme in Escherichia coli strain BL21-AI
overexpression in an enzyme-deficient Escherichia coli strain
-
recombinant expression of wild-type and mutant enzymes in Escherichia coli strain Sphi609
APPLICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
medicine
the enzyme is an anti-malarial drug target
drug development
medicine
-
potential target for antiparasitic chemotherapy
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Keough, D.T.; Ng, A.L.; Winzor, D.J.; Emmerson, B.T.; de Jersey, J.
Purification and characterization of Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase and comparison with the human enzyme
Mol. Biochem. Parasitol.
98
29-41
1999
Homo sapiens, Plasmodium falciparum
Manually annotated by BRENDA team
Sujay Subbayya, I.N.; Sukumaran, S.; Shivashankar, K.; Balaram, H.
Unusual substrate specificity of a chimeric hypoxanthine-guanine phosphoribosyltransferase containing segments from the Plasmodium falciparum and human enzymes
Biochem. Biophys. Res. Commun.
272
596-602
2000
Homo sapiens, Plasmodium falciparum
Manually annotated by BRENDA team
Raman, J.; Sumathy, K.; Anand, R.P.; Balaram, H.
A non-active site mutation in human hypoxanthine guanine phosphoribosyltransferase expands substrate specificity
Arch. Biochem. Biophys.
427
116-122
2004
Plasmodium falciparum, Homo sapiens (P00492), Homo sapiens
Manually annotated by BRENDA team
Raman, J.; Ashok, C.S.; Subbayya, S.I.; Anand, R.P.; Selvi, S.T.; Balaram, H.
Plasmodium falciparum hypoxanthine guanine phosphoribosyltransferase. Stability studies on the product-activated enzyme
FEBS J.
272
1900-1911
2005
Plasmodium falciparum
Manually annotated by BRENDA team
Mbewe, B.; Chibale, K.; McIntosh, D.B.
Purification of human malaria parasite hypoxanthine guanine xanthine phosphoribosyltransferase (HGXPRT) using immobilized Reactive Red 120
Protein Expr. Purif.
52
153-158
2007
Plasmodium falciparum
Manually annotated by BRENDA team
Keough, D.T.; Hockova, D.; Holy, A.; Naesens, L.M.; Skinner-Adams, T.S.; Jersey, J.; Guddat, L.W.
Inhibition of hypoxanthine-guanine phosphoribosyltransferase by acyclic nucleoside phosphonates: a new class of antimalarial therapeutics
J. Med. Chem.
52
4391-4399
2009
Plasmodium falciparum, Homo sapiens (P00492), Homo sapiens
Manually annotated by BRENDA team
Gayathri, P.; Sujay Subbayya, I.; Ashok, C.; Senthamizh Selvi, T.; Balaram, H.; Murthy, M.
Crystal structure of a chimera of human and Plasmodium falciparum hypoxanthine guanine phosphoribosyltransferases provides insights into oligomerization
Proteins
73
1010-1020
2008
Homo sapiens (P00492), Homo sapiens, Plasmodium falciparum (P20035), Plasmodium falciparum
Manually annotated by BRENDA team
Gogia, S.; Balaram, H.; Puranik, M.
Hypoxanthine guanine phosphoribosyltransferase distorts the purine ring of nucleotide substrates and perturbs the pKa of bound xanthosine monophosphate
Biochemistry
50
4184-4193
2011
Plasmodium falciparum, Homo sapiens (P00492), Homo sapiens
Manually annotated by BRENDA team
Hazleton, K.Z.; Ho, M.C.; Cassera, M.B.; Clinch, K.; Crump, D.R.; Rosario, I.; Merino, E.F.; Almo, S.C.; Tyler, P.C.; Schramm, V.L.
Acyclic immucillin phosphonates: second-generation inhibitors of Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase
Chem. Biol.
19
721-730
2012
Plasmodium falciparum
Manually annotated by BRENDA team
Clinch, K.; Crump, D.R.; Evans, G.B.; Hazleton, K.Z.; Mason, J.M.; Schramm, V.L.; Tyler, P.C.
Acyclic phosph(on)ate inhibitors of Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase
Bioorg. Med. Chem.
21
5629-5646
2013
Homo sapiens, Plasmodium falciparum (P20035)
Manually annotated by BRENDA team
Karnawat, V.; Gogia, S.; Balaram, H.; Puranik, M.
Differential distortion of purine substrates by human and Plasmodium falciparum hypoxanthine-guanine phosphoribosyltransferase to catalyse the formation of mononucleotides
ChemPhysChem
16
2172-2181
2015
Homo sapiens (P00492), Homo sapiens, Plasmodium falciparum (P20035), Plasmodium falciparum
Manually annotated by BRENDA team
Roy, S.; Nagappa, L.K.; Prahladarao, V.S.; Balaram, H.
Kinetic mechanism of Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase
Mol. Biochem. Parasitol.
204
111-120
2015
Plasmodium falciparum (P20035), Plasmodium falciparum
Manually annotated by BRENDA team
Roy, S.; Karmakar, T.; Prahlada Rao, V.S.; Nagappa, L.K.; Balasubramanian, S.; Balaram, H.
Slow ligand-induced conformational switch increases the catalytic rate in Plasmodium falciparum hypoxanthine guanine xanthine phosphoribosyltransferase
Mol. Biosyst.
11
1410-1424
2015
Plasmodium falciparum (P20035), Plasmodium falciparum
Manually annotated by BRENDA team
Keough, D.T.; Rejman, D.; Pohl, R.; Zbornikova, E.; Hockova, D.; Croll, T.; Edstein, M.D.; Birrell, G.W.; Chavchich, M.; Naesens, L.M.J.; Pierens, G.K.; Brereton, I.M.; Guddat, L.W.
Design of Plasmodium vivax hypoxanthine-guanine phosphoribosyltransferase inhibitors as potential antimalarial therapeutics
ACS Chem. Biol.
13
82-90
2018
Plasmodium falciparum (A0A1G4HBT9), Plasmodium falciparum (Q8IJS1), Plasmodium falciparum, Homo sapiens (P00492)
Manually annotated by BRENDA team
Ducati, R.G.; Firestone, R.S.; Schramm, V.L.
Kinetic isotope effects and transition state structure for hypoxanthine-guanine-xanthine phosphoribosyltransferase from Plasmodium falciparum
Biochemistry
56
6368-6376
2017
Plasmodium falciparum (Q8IJS1)
Manually annotated by BRENDA team
Opoku, F.; Govender, P.P.; Pooe, O.J.; Simelane, M.B.C.
Evaluating iso-mukaadial acetate and ursolic acid acetate as Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase inhibitors
Biomolecules
9
861
2019
Plasmodium falciparum (Q8IJS1)
Manually annotated by BRENDA team
Spacek, P.; Keough, D.T.; Chavchich, M.; Dracinsky, M.; Janeba, Z.; Naesens, L.; Edstein, M.D.; Guddat, L.W.; Hockova, D.
Synthesis and evaluation of asymmetric acyclic nucleoside bisphosphonates as inhibitors of Plasmodium falciparum and human hypoxanthine-guanine-(xanthine) phosphoribosyltransferase
J. Med. Chem.
60
7539-7554
2017
Homo sapiens (P00492), Homo sapiens, Plasmodium falciparum (Q8IJS1), Plasmodium falciparum
Manually annotated by BRENDA team
Roy, S.; Karmakar, T.; Nagappa, L.K.; Prahlada Rao, V.S.; Balasubramanian, S.; Balaram, H.
Role of W181 in modulating kinetic properties of Plasmodium falciparum hypoxanthine guanine xanthine phosphoribosyltransferase
Proteins
84
1658-1669
2016
Plasmodium falciparum (Q8IJS1), Plasmodium falciparum
Manually annotated by BRENDA team